Impelling Times for Tissue Section Proteomics in Lymphoma

Abstract

Lymphoma drug development in the modern era focuses on identifying inhibitors of gene products directly involved in the pathogenesis of lymphoid malignancies. These new molecularly targeted drugs are more selective and specific for lymphoma subtypes that express the variant gene product. Therapy-relevant targets have traditionally been identified through molecular testing methodologies such as polymerase chain reaction, fluorescent in situ hybridization (FISH), and massive parallel sequencing or next-generation sequencing (NGS) methods. The latter can serve as screening or definitive tests, highlighting the presence of targeted gene variants and helping in selecting the most appropriate agents for clinical use or further research.